Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xenon (XENE – Research Report), Arvinas Holding Company (ARVN – Research Report) and Esperion (ESPR – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xenon (XENE)
In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Buy rating on Xenon, with a price target of $50.00. The company’s shares closed last Tuesday at $43.79.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $55.92, a 34.6% upside from current levels. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.
See today’s best-performing stocks on TipRanks >>
Arvinas Holding Company (ARVN)
Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating on Arvinas Holding Company yesterday and set a price target of $14.00. The company’s shares closed last Tuesday at $13.36.
According to TipRanks.com, Ahmad is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arvinas Holding Company with a $15.73 average price target, implying a 21.2% upside from current levels. In a report issued on February 25, TipRanks – Google also downgraded the stock to Hold with a $12.50 price target.
Esperion (ESPR)
In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion, with a price target of $1.78. The company’s shares closed last Tuesday at $2.91.
According to TipRanks.com, Zemansky is a 5-star analyst with an average return of
Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $8.16.
